Literature DB >> 3499682

Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis.

M F López-Fernández1, C López-Berges, R Martín, A Pardo, F J Ramos, J Batlle.   

Abstract

The multimeric and subunit patterns of plasma von Willebrand factor (vWF) were analyzed in eight patients with myeloproliferative syndrome (MS) in order to investigate the possible existence of heterogeneity in the "in vivo" proteolytic cleavage of the protein, previously observed in this entity. Six patients lacked large vWF multimers, five of them having normal bleeding times (BT) and clinically documented episodes of thrombotic origin, whereas one patient had long BT and bleeding symptoms. Seven patients showed a relative increase in the 176 kDa subunit fragment while the 189 kDa polypeptide was increased in only one. In addition, another patient (and prior to any therapy) showed the presence of a new fragment of approximately 95 kDa which disappeared after Busulfan therapy. The collection of blood from these patients with proteinase inhibitors did not correct the abnormalities. The infusion of DDAVP to two patients with abnormal vWF was accompanied by: the appearance of larger vWF multimers which disappeared rapidly from plasma; an increase in the relative proportion of the satellite bands of each multimer and a further increase of the 176 kDa fragment. These data point to some heterogeneity in the vWF abnormality present in MS which may be related in part to a variable degree of proteolysis of vWF occurring "in vivo" rather than "in vitro", and which may be associated to either a thrombotic or a bleeding diathesis. They also suggest that despite the presence of abnormal, already proteolyzed vWF, DDAVP-enhanced proteolysis occurs in MS to a similar extent to what is described in normal individuals.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499682

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Characterization of von Willebrand factor in primary pulmonary hypertension.

Authors:  M T Collados; J Sandoval; S López; F A Massó; A Páez; J R Borbolla; L F Montaño
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

2.  Clinical effectiveness of desmopressin in a case of acquired von Willebrand's syndrome associated with benign monoclonal gammopathy.

Authors:  G Castaman; F Rodeghiero; E Di Bona; M Ruggeri
Journal:  Blut       Date:  1989-04

3.  Haemostatic Profile in Patients of Myeloproliferative Neoplasms-A Tertiary Care Centre Experience.

Authors:  Yatendra Parashar; Rashmi Kushwaha; Ashutosh Kumar; Kamal Agarwal; U S Singh; Mili Jain; S P Verma; A K Tripathi
Journal:  J Clin Diagn Res       Date:  2016-11-01

4.  Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.

Authors:  P J van Genderen; J J Michiels; S C van der Poel-van de Luytgaarde; H H van Vliet
Journal:  Ann Hematol       Date:  1994-08       Impact factor: 3.673

5.  Acquired von Willebrand's disease.

Authors:  B J Hennessy; B White; M Byrne; O P Smith
Journal:  Ir J Med Sci       Date:  1998 Apr-Jun       Impact factor: 1.568

6.  Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia.

Authors:  Monica Sacco; Paola Ranalli; Stefano Lancellotti; Giovanna Petrucci; Alfredo Dragani; Bianca Rocca; Raimondo De Cristofaro
Journal:  Res Pract Thromb Haemost       Date:  2020-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.